ArticleNeurochemical research2003
Increased fibrillar beta-amyloid in response to human clq injections into hippocampus and cortex of APP+PS1 transgenic mice.
Article in Neurochemical research, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The complement cascade in Alzheimer's disease: a systematic review and meta-analysis.Molecular psychiatry · 2021Pooled it
- Article
- Young adult microglial deletion of C1q reduces engulfment of synapses and prevents cognitive impairment in an aggressive Alzheimer's disease mouse model.bioRxiv : the preprint server for biology · 2025Article
- From Small Peptides to Large Proteins against Alzheimer'sDisease.Biomolecules · 2022Review
- Free complement and complement containing extracellular vesicles as potential biomarkers for neuroinflammatory and neurodegenerative disorders.Frontiers in immunology · 2022Review
- Article
- The effect of insomnia on development of Alzheimer's disease.Journal of neuroinflammation · 2020Review
- C1q ablation exacerbates amyloid deposition: A study in a transgenic mouse model of ATTRV30M amyloid neuropathy.PloS one · 2017Article
- Immunotherapy for Alzheimer's disease.Biochemical pharmacology · 2014Review
- Novel immunological approaches for the treatment of Alzheimer's disease.Zhongguo xian dai shen jing ji bing za zhi · 2014Article
- What does complement do in Alzheimer's disease? Old molecules with new insights.Translational neurodegeneration · 2013Article
- Amyloid-beta immunotherapy for Alzheimer's disease.CNS & neurological disorders drug targets · 2010Review
- Preventing beta-amyloid fibrillization and deposition: beta-sheet breakers and pathological chaperone inhibitors.BMC neuroscience · 2008Review
- Amyloid-beta immunisation for Alzheimer's disease.The Lancet. Neurology · 2008Review
- Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2008Review
- Immunological and anti-chaperone therapeutic approaches for Alzheimer disease.Brain pathology (Zurich, Switzerland) · 2005Review
- Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Human C1q when injected directly into hippocampus and cortex of doubly transgenic APP+PS1 mice results in the increase of Congo red-positive fibrillar deposits. Although there was no significant change in overall area stained for Abeta total, qualitatively it appeared that there was less diffuse Abeta in C1q-treated mice versus vehicle. There was no apparent change in astroglial or microglial activation caused by injection of C1q with respect to vehicle injections. These effects of C1q were only found in 50% BUB/BnJ mice, a strain with higher serum complement activity than other mouse lines. These in vivo data were consistent with the effects of C1q to increase fibrillogenesis of Abeta in vitro. In conclusion, complement protein C1q, believed to be involved in the pathogenesis of Alzheimer's disease in humans, can cause increased fibrillogenesis in the APP+PS1 mouse model of amyloid deposition.
Indexed as
Identifiers
12587666What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.